down-arrowleft-arrowright-arrow

SERVICES

Life Sciences Litigation

Overview

Haug Partners’ Life Sciences Litigation team is recognized nationwide for its excellence in representing global pharmaceutical, biotechnology, and medical device companies, including in complex commercial matters and actions brought under the Hatch Waxman Act. Our team is comprised of experienced trial attorneys, scientific advisors, and registered patent attorneys, many of whom have advanced degrees in specialized technical fields such as molecular and cellular biology, biochemistry, organic chemistry, and pharmacology, coupled with extensive hands-on experience in the life sciences industry. Our litigators are able to draw on their legal and scientific expertise to explain complicated legal and technical concepts to judges and juries.

Life Sciences Litigation has been the lifeblood of the firm since its founding in 1997. Haug Partners’ unique, cross-functional biotechnology and biopharmaceutical litigation, patent litigation, and FDA practices also enable our Life Sciences Litigation team to provide seamless, interdisciplinary counseling and representation across all phases of a litigation lifecycle, from pre-suit strategy and patent analysis to appeals before the Court of Appeals for the Federal Circuit. Haug Partners regularly appears before state and federal courts across the country, as well as the Patent Trial and Appeal Board. Because many life sciences disputes are global in scope, Haug Partners is adept at developing strategies that cross borders.

Haug Partners has appeared as lead trial counsel in about two hundred Hatch-Waxman litigations in its twenty-three year history, involving more than sixty different pharmaceutical products. The Life Sciences Litigation team’s achievements include successfully representing or obtaining favorable settlements on behalf of global pharmaceutical companies for drug products such as:

  • Firazyr® (icatibant injection)
  • Mydayis® (mixed salts of a single-entity amphetamine product)
  • Haegarda® (C1 Esterase Inhibitor Subcutaneous [Human])
  • Gattex® (teduglutide)
  • Trokendi XR® (topiramate)
  • Cardene® (nicardipine hydrochloride)
  • Adderall XR® (mixed salts of a single-entity amphetamine product)
  • Vyvanse® (lisdexamfetamine dimesylate)
  • Oxtellar XR® (oxcarbazepine)
  • Lialda® (mesalamine)

What We Do

  • Patent infringement litigation
  • Appellate litigation
  • Commercial litigation
  • Consumer products litigation
  • PTAB Post-Issuance proceedings
  • Mediation
  • Arbitration

Services

  • Anti-Counterfeiting
  • Antitrust Counseling
  • Antitrust Government Investigation
  • Antitrust Litigation
  • Appellate Litigation
  • Automotive Litigation
  • Biotechnology Litigation
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Products Litigation
  • Copyright
  • Due Diligence
    & Investigations
  • FDA
  • Hatch-Waxman Litigation
  • Intellectual Property Litigation
  • ITC Litigation
  • Latin America Practice
  • Licensing
    & Transactions
  • Patent Prosecution
  • PTAB Post-Issuance Proceedings
  • Trade Secret Litigation
  • Trademarks
    & Unfair Competition

Haug Partners LLP
+1.212.588.0800
haugpartners.com
©2020 Haug Partners

Life Sciences Litigation

Overview

Haug Partners’ Life Sciences Litigation team is recognized nationwide for its excellence in representing global pharmaceutical, biotechnology, and medical device companies, including in complex commercial matters and actions brought under the Hatch Waxman Act. Our team is comprised of experienced trial attorneys, scientific advisors, and registered patent attorneys, many of whom have advanced degrees in specialized technical fields such as molecular and cellular biology, biochemistry, organic chemistry, and pharmacology, coupled with extensive hands-on experience in the life sciences industry. Our litigators are able to draw on their legal and scientific expertise to explain complicated legal and technical concepts to judges and juries.

Life Sciences Litigation has been the lifeblood of the firm since its founding in 1997. Haug Partners’ unique, cross-functional biotechnology and biopharmaceutical litigation, patent litigation, and FDA practices also enable our Life Sciences Litigation team to provide seamless, interdisciplinary counseling and representation across all phases of a litigation lifecycle, from pre-suit strategy and patent analysis to appeals before the Court of Appeals for the Federal Circuit. Haug Partners regularly appears before state and federal courts across the country, as well as the Patent Trial and Appeal Board. Because many life sciences disputes are global in scope, Haug Partners is adept at developing strategies that cross borders.

Haug Partners has appeared as lead trial counsel in about two hundred Hatch-Waxman litigations in its twenty-three year history, involving more than sixty different pharmaceutical products. The Life Sciences Litigation team’s achievements include successfully representing or obtaining favorable settlements on behalf of global pharmaceutical companies for drug products such as:

  • Firazyr® (icatibant injection)
  • Mydayis® (mixed salts of a single-entity amphetamine product)
  • Haegarda® (C1 Esterase Inhibitor Subcutaneous [Human])
  • Gattex® (teduglutide)
  • Trokendi XR® (topiramate)
  • Cardene® (nicardipine hydrochloride)
  • Adderall XR® (mixed salts of a single-entity amphetamine product)
  • Vyvanse® (lisdexamfetamine dimesylate)
  • Oxtellar XR® (oxcarbazepine)
  • Lialda® (mesalamine)

What We Do

  • Patent infringement litigation
  • Appellate litigation
  • Commercial litigation
  • Consumer products litigation
  • PTAB Post-Issuance proceedings
  • Mediation
  • Arbitration